American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Regeneron Pharmaceuticals Inc

REGN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

REGN historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of REGN by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Purchase $1,001 - $15,000 Jul 07, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 Jun 16, 2026
Ro Khanna House / D Sale $1,001 - $15,000 Jun 02, 2026
Ro Khanna House / D Sale $1,001 - $15,000 May 15, 2026
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 May 15, 2026
Ro Khanna House / D Sale $1,001 - $15,000 May 01, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 13, 2026
Alan Armstrong Senate / R Purchase $1,001 - $15,000 Mar 27, 2026
Julia Letlow House / R Purchase $1,001 - $15,000 Feb 12, 2026
Ro Khanna House / D Sale $1,001 - $15,000 Jan 29, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 23, 2026
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Nov 18, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 03, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Sep 29, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 26, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 26, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 04, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 04, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Jul 25, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Jul 25, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Jul 01, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Jul 01, 2025
Ro Khanna House / D Sale $1,001 - $15,000 May 28, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 May 19, 2025
Robert Bresnahan House / R Purchase $1,001 - $15,000 May 15, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Apr 15, 2025
Byron Donalds House / R Sale $1,001 - $15,000 Apr 10, 2025
Byron Donalds House / R Sale $1,001 - $15,000 Apr 10, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 09, 2025
Robert Bresnahan House / R Sale $1,001 - $15,000 Apr 08, 2025
Jefferson Shreve House / R Sale $15,001 - $50,000 Apr 07, 2025
Julie Johnson House / D Sale $1,001 - $15,000 Apr 01, 2025
Robert Bresnahan House / R Sale $1,001 - $15,000 Feb 25, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 25, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 19, 2025
Julie Johnson House / D Sale $1,001 - $15,000 Feb 12, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 Jan 24, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 17, 2025
Julie Johnson House / D Purchase $1,001 - $15,000 Jan 15, 2025
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov 29, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov 19, 2024
Jonathan L. Jackson House / D Sale $15,001 - $50,000 Nov 13, 2024
Ro Khanna House / D Sale $1,001 - $15,000 Nov 12, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Byron Donalds House / R Exchange $1,001 - $15,000 N/A
Jonathan L. Jackson House / D Sale $1,001 - $15,000 Nov 01, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Oct 23, 2024
Greg Landsman House / D Sale $1,001 - $15,000 Oct 15, 2024
REGN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
REGN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
REGN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in REGN holdings by institutional investors

Insider Trading

Quarterly net insider trading by REGN's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $630,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $640,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $610,000 Jan 20, 2026 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
  • $570,000 Oct 20, 2025 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark
  • $610,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $400,000 Apr 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
  • $400,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
  • $400,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $400,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $430,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $400,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Jul 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $320,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $320,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $340,000 Jul 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Apr 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Jan 20, 2022 Issue: None
  • $360,000 Oct 20, 2021 Issue: None
  • $310,000 Jul 20, 2021 Issue: None
  • $330,000 Apr 20, 2021 Issue: None
  • $330,000 Jan 21, 2021 Issue: None
  • $480,000 Oct 20, 2020 Issue: None
  • $320,000 Jul 20, 2020 Issue: None
  • $370,000 Apr 20, 2020 Issue: None
  • $340,000 Jan 21, 2020 Issue: None
  • $180,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
  • $250,000 Jul 22, 2019 Issue: Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues Medicare/Medicaid
  • $300,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $90,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $180,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $190,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $200,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $260,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $120,000 Oct 20, 2017 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $120,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Budget/Appropriations
  • $240,000 Apr 20, 2017 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $130,000 Jan 20, 2017 Issue: Health Issues Medicare/Medicaid
  • $130,000 Oct 20, 2016 Issue: Health Issues
  • $120,000 Jul 20, 2016 Issue: Health Issues
  • $50,000 Apr 19, 2016 Issue: Health Issues
  • $50,000 Jan 16, 2016 Issue: Health Issues
  • $50,000 Oct 20, 2015 Issue: Health Issues
  • $50,000 Jul 20, 2015 Issue: Health Issues
  • $60,000 Apr 20, 2015 Issue: Health Issues
  • $52,000 Jan 19, 2015 Issue: Health Issues
  • $50,000 Oct 20, 2014 Issue: Health Issues
  • $50,000 Jul 21, 2014 Issue: Health Issues
  • $50,000 Jan 22, 2014 Issue: Health Issues
  • $50,000 Oct 21, 2013 Issue: Health Issues
  • $40,000 Jul 22, 2013 Issue: Health Issues
  • $30,000 Apr 24, 2013 Issue: Health Issues
  • $30,000 Feb 02, 2013 Issue: Health Issues
  • $30,000 Oct 31, 2012 Issue: Health Issues
Revolving Door

Former government officials who have lobbied for REGN

32 former government officials from 25 congressional offices at 8 lobbying firms have lobbied for REGN, most recently Aug 03, 2026.

  • Barbara A. Mikulski
    Steven Crane Senate Staff assistant, Senator Barbara Mikulski Formerly with Barbara A. Mikulski · CRANE STRATEGIES · Aug 03, 2026
  • Tom Bliley
    Brent Del Monte House Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee Formerly with Tom Bliley · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Ron Wyden
    Raghav Aggarwal Senate Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior Formerly with Ron Wyden · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Elizabeth Warren
    Remy Mason Senate Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz Formerly with Elizabeth Warren · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Debbie Wasserman Schultz
    Daniel Farmer House Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space Formerly with Debbie Wasserman Schultz · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • John Stone House Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C Formerly Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Richard Hudson
    Timothy Blanchat House Chief of Staff, Congressman Richard Hudson; Deputy State Director, Senator Thom Tillis Formerly with Richard Hudson · CHECKMATE GOVERNMENT RELATIONS · Jul 15, 2026
  • Gregory Nickerson Congress Tax Counsel, Ways and Means Committee; Staff Director, Ways and Means Select Revenue Measures Subcommittee Formerly Tax Counsel, Ways and Means Committee; Staff Director, Ways and Means Select Rev · THE WASHINGTON TAX & PUBLIC POLICY GROUP · Jul 08, 2026
See all 32 on the Revolving Door dashboard
Corporate Lobbying

REGN Estimated quarterly lobbying spending

Revenue Breakdown

REGN Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
REGN Income Statement
REGN Balance Sheet
REGN Cash Flow
U.S. Patents

New REGN patent grants

  • Patent Title: Retainer adapter assembly Jul. 14, 2026
  • Patent Title: Retainer adapter assembly Jul. 14, 2026
  • Patent Title: Wearable autoinjector Apr. 14, 2026
  • Patent Title: Dose delivery device Mar. 24, 2026
  • Patent Title: Dose delivery device Mar. 03, 2026
  • Patent Title: Drug-delivery device Jan. 13, 2026
  • Patent Title: Drug-delivery device Jan. 06, 2026
  • Patent Title: Retainer adapter assembly Jan. 14, 2025
  • Patent Title: Packaging Oct. 22, 2024
  • Patent Title: Packaging Sep. 17, 2024
  • Patent Title: Support for test device Aug. 20, 2024
  • Patent Title: Packaging Jul. 16, 2024
  • Patent Title: Retainer adapter assembly May. 21, 2024
  • Patent Title: Retainer adapter assembly Apr. 23, 2024
  • Patent Title: Wearable autoinjector Dec. 12, 2023
  • Patent Title: Packaging Aug. 23, 2022
  • Patent Title: Packaging Aug. 23, 2022
  • Patent Title: Auto-injector cap Jul. 26, 2022
  • Patent Title: Genetically modified mouse with an inducible acvr1 gene with a mutant r206h exon 5 that has ectopic bone formation Jul. 05, 2022
  • Patent Title: Packaging Oct. 26, 2021
  • Patent Title: Auto-injector cap Sep. 28, 2021
  • Patent Title: Production cell line enhancers Jul. 20, 2021
  • Patent Title: Packaging Dec. 29, 2020
  • Patent Title: Auto-injector Dec. 01, 2020
  • Patent Title: Syringe cap Sep. 03, 2019
  • Patent Title: Nucleic acid construct for making a genetically modified rodent with an inducible acvr1 mutation that causes ectopic bone formation Jun. 19, 2018
  • Patent Title: Human antibodies to pd-1 Jun. 05, 2018
  • Patent Title: Genetically modified non-human animals and methods of use thereof Jun. 05, 2018
  • Patent Title: Readily isolated bispecific antibodies with native immunoglobulin format May. 29, 2018
  • Patent Title: Humanized il-7 rodents May. 22, 2018
  • Patent Title: Methods for making fully human bispecific antibodies using a common light chain May. 15, 2018
  • Patent Title: Methods and compositions comprising a combination of a vegf trap and an anti-ctla-4 antibody May. 15, 2018
  • Patent Title: Antibody modulators of aplnr May. 09, 2017
  • Patent Title: Il-33 antagonists and uses thereof May. 02, 2017
  • Patent Title: Vegf specific fusion protein antagonist formulations May. 02, 2017
  • Patent Title: Systems and trays for processing samples by a robotic platform Apr. 25, 2017
  • Patent Title: Non-human animals having a humanized b-cell activating factor gene Apr. 25, 2017
  • Patent Title: Humanized il-6 and il-6 receptor Apr. 18, 2017
  • Patent Title: Humanized light chain mice Apr. 18, 2017
  • Patent Title: Genetically modified major histocompatibility complex mice Apr. 11, 2017
  • Patent Title: Angiopoietin-based interventions for treating cerebral malaria Mar. 14, 2017
  • Patent Title: Genetically modified major histocompatibility complex animals Mar. 14, 2017
  • Patent Title: Human antibodies to the glucagon receptor and methods of use thereof Mar. 07, 2017
  • Patent Title: Genetically modified major histocompatibility complex mice Mar. 07, 2017
  • Patent Title: Nuclease-mediated dna assembly Feb. 28, 2017
  • Patent Title: Vegf antagonist formulations suitable for intravitreal administration Feb. 28, 2017
  • Patent Title: Humanized il-4 and il-4rα animals Feb. 14, 2017
  • Patent Title: Enhanced expression and stability regions Feb. 07, 2017
  • Patent Title: Method of treating a tl1a-associated disease or disorder with human antibodies to tl1a Jan. 31, 2017
  • Patent Title: Incrna-knockout mice Jan. 31, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to REGN from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
REGN News

Recent insights relating to REGN

CNBC Recommendations

Recent picks made for REGN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in REGN

REGN Analyst Ratings

REGN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
REGN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $REGN stock a Buy, Sell, or Hold?

  • What is the price target for $REGN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

REGN Top Shareholders
Shareholder
Shares Held
REGN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $REGN stock?

  • Who owns the most shares of $REGN stock?

  • What funds own $REGN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

REGN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view REGN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About REGN

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

  • Address Tarrytown, NY
  • Market Cap 81.1 billion
  • Employees 15,410
  • Industrial Classification Pharmaceutical Preparations

Regeneron Pharmaceuticals Inc (REGN) Historical Stock Prices

Regeneron Pharmaceuticals Inc (REGN) closed at $788.04 on September 25, 2026. Over the past year its adjusted close ranged from $552.74 to $852.03. Daily prices go back to January 2, 2014, 3,201 trading days in all.

  • 1 month-3.28%
  • 3 months+24.66%
  • Year to date+2.48%
  • 1 year+42.57%
  • 3 years-4.45%
  • 5 years+24.49%
  • Max+189.65%
See every congressional and insider trade on the REGN price chart

Quiver Premium charts REGN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 25, 2026 803.87 803.87 784.13 788.04 788.04 592,145
Sep 24, 2026 801.59 807.21 789.39 796.02 796.02 602,653
Sep 23, 2026 805.23 813.53 790.02 801.82 801.82 721,110
Sep 22, 2026 802.48 811.66 791.31 803.90 803.90 600,266
Sep 21, 2026 786.03 801.44 779.96 798.17 798.17 704,526
Sep 18, 2026 787.34 794.73 779.65 784.85 784.85 2,473,436
Sep 17, 2026 781.18 789.99 774.77 789.45 789.45 702,816
Sep 16, 2026 775.82 779.98 771.80 774.61 774.61 382,945
Sep 15, 2026 788.53 788.58 769.57 774.11 774.11 540,837
Sep 14, 2026 791.98 798.84 779.45 793.74 793.74 591,295
Sep 11, 2026 800.00 800.22 780.81 781.49 781.49 443,986
Sep 10, 2026 794.36 806.14 792.00 793.26 793.26 526,911
Sep 9, 2026 803.83 808.63 796.73 807.65 807.65 621,458
Sep 8, 2026 814.36 821.17 799.42 810.31 810.31 556,536
Sep 4, 2026 840.05 841.54 825.83 827.72 827.72 561,170
Sep 3, 2026 858.18 859.34 837.63 843.47 843.47 496,255
Sep 2, 2026 826.24 854.49 825.77 852.03 852.03 749,453
Sep 1, 2026 808.86 824.63 804.32 823.82 823.82 682,806
Aug 31, 2026 782.44 802.78 779.08 799.08 799.08 894,268
Aug 28, 2026 809.40 809.40 789.08 794.19 794.19 488,305
Aug 27, 2026 806.18 817.62 804.27 807.71 807.71 766,990
Aug 26, 2026 827.78 831.67 814.70 814.79 814.79 585,370
Aug 25, 2026 829.22 839.94 823.44 833.56 833.56 505,424
Aug 24, 2026 834.51 834.70 823.39 828.50 828.50 672,012
Aug 21, 2026 835.74 847.00 826.64 834.04 834.04 786,921
Aug 20, 2026 831.70 840.82 826.05 826.64 826.64 596,474
Aug 19, 2026 817.17 844.92 815.38 840.84 840.84 750,445
Aug 18, 2026$0.94 dividend 814.00 821.02 805.93 810.24 810.24 779,072
Aug 17, 2026 801.76 813.18 795.73 805.93 805.00 541,306
Aug 14, 2026 802.35 806.53 792.57 803.48 802.55 425,600
Aug 13, 2026 802.21 815.80 794.49 805.97 805.04 709,747
Aug 12, 2026 790.55 801.36 784.61 797.99 797.07 575,164
Aug 11, 2026 808.80 813.63 796.66 797.00 796.08 939,190
Aug 10, 2026 781.72 809.09 775.83 808.05 807.11 1,213,798
Aug 7, 2026 774.47 785.99 767.17 784.36 783.45 837,598
Aug 6, 2026 777.85 780.95 762.78 772.11 771.22 783,950
Aug 5, 2026 767.98 782.59 763.31 768.58 767.69 532,482
Aug 4, 2026 753.76 763.54 747.00 760.66 759.78 817,280
Aug 3, 2026 769.54 772.75 756.44 759.24 758.36 842,730
Jul 31, 2026 726.69 764.75 724.79 762.63 761.75 1,158,583
Jul 30, 2026 701.89 740.00 694.98 738.34 737.48 1,460,963
Jul 29, 2026 699.38 702.60 691.00 695.42 694.61 1,022,421
Jul 28, 2026 676.93 696.74 676.46 695.18 694.37 900,408
Jul 27, 2026 661.77 678.12 659.53 667.17 666.40 650,984
Jul 24, 2026 658.29 667.50 654.05 656.01 655.25 708,392
Jul 23, 2026 646.48 655.20 637.80 651.91 651.15 1,129,411
Jul 22, 2026 676.43 676.79 648.90 651.18 650.42 872,170
Jul 21, 2026 672.55 678.67 666.87 675.19 674.41 529,783
Jul 20, 2026 674.72 681.74 669.88 672.15 671.37 624,791
Jul 17, 2026 676.05 691.13 672.31 676.69 675.91 648,400
Jul 16, 2026 666.28 680.29 661.38 678.94 678.15 730,245
Jul 15, 2026 656.11 669.10 648.66 664.45 663.68 555,419
Jul 14, 2026 658.00 663.10 653.31 656.12 655.36 477,991
Jul 13, 2026 661.63 665.60 655.11 663.09 662.32 606,304
Jul 10, 2026 670.06 676.66 658.50 664.52 663.75 581,778
Jul 9, 2026 660.80 669.16 660.80 667.95 667.18 672,528
Jul 8, 2026 669.11 670.35 661.43 662.88 662.11 746,834
Jul 7, 2026 663.18 677.92 659.02 676.23 675.45 918,937
Jul 6, 2026 657.96 657.96 637.72 649.81 649.06 714,338
Jul 2, 2026 630.52 654.93 625.70 654.27 653.51 1,071,604
Jul 1, 2026 629.90 632.85 623.89 624.72 624.00 1,170,657
Jun 30, 2026 630.95 634.06 622.29 623.54 622.82 820,925
Jun 29, 2026 635.99 638.30 626.86 631.81 631.08 734,528
Jun 26, 2026 623.64 638.76 623.44 632.90 632.17 1,213,634
Jun 25, 2026 623.16 634.31 619.70 620.14 619.42 696,862
Jun 24, 2026 621.63 631.18 619.27 623.43 622.71 839,934
Jun 23, 2026 607.92 621.79 607.92 618.03 617.31 1,279,871
Jun 22, 2026 604.46 613.56 594.90 612.50 611.79 1,604,297
Jun 18, 2026 612.07 616.24 598.19 609.94 609.23 2,609,258
Jun 17, 2026 615.16 620.00 602.13 607.93 607.23 1,299,691
Jun 16, 2026 615.18 617.60 608.21 614.73 614.02 1,007,463
Jun 15, 2026 613.35 615.95 608.59 614.98 614.27 815,879
Jun 12, 2026 613.11 616.54 605.01 612.14 611.43 717,780
Jun 11, 2026 604.31 618.10 603.57 611.48 610.77 943,173
Jun 10, 2026 619.07 619.25 601.22 601.65 600.95 816,110
Jun 9, 2026 624.17 628.90 610.95 616.18 615.47 1,190,659
Jun 8, 2026 638.04 638.95 608.98 611.34 610.63 1,259,234
Jun 5, 2026 632.26 640.82 632.09 635.45 634.71 975,793
Jun 4, 2026 628.07 633.88 621.11 628.73 628.00 974,745
Jun 3, 2026 600.79 625.00 599.00 618.95 618.23 986,685
Jun 2, 2026 596.52 604.63 591.52 602.92 602.22 1,067,006
Jun 1, 2026 607.54 614.00 598.79 600.66 599.96 1,080,307
May 29, 2026 620.11 624.47 609.77 614.78 614.07 2,187,707
May 28, 2026 630.15 631.73 620.35 621.52 620.80 1,234,667
May 27, 2026 634.80 638.06 625.00 627.74 627.01 1,913,613
May 26, 2026 642.45 648.50 632.68 634.62 633.88 889,901
May 22, 2026 639.24 644.12 632.72 638.88 638.14 995,023
May 21, 2026 645.00 650.32 639.81 642.59 641.85 1,178,558
May 20, 2026$0.94 dividend 634.32 651.00 633.60 649.76 649.01 1,165,758
May 19, 2026 630.49 639.99 616.02 630.30 628.66 1,445,135
May 18, 2026 615.93 633.00 610.60 629.68 628.04 2,996,891
May 15, 2026 712.69 717.88 693.70 698.25 696.43 728,233
May 14, 2026 719.00 722.51 710.06 712.87 711.01 767,205
May 13, 2026 721.29 730.59 709.51 719.88 718.01 879,367
May 12, 2026 716.39 725.60 710.02 723.41 721.53 824,575
May 11, 2026 714.99 727.38 701.99 712.77 710.92 1,227,186
May 8, 2026 709.29 717.99 708.36 714.89 713.03 589,041
May 7, 2026 718.50 725.31 707.43 709.10 707.25 774,679
May 6, 2026 703.33 726.16 702.50 721.05 719.17 739,914
May 5, 2026 710.73 715.62 699.23 702.27 700.44 642,799
May 4, 2026 702.56 711.55 699.75 709.21 707.37 554,271
May 1, 2026 703.02 714.48 700.26 701.42 699.60 729,185
Apr 30, 2026 693.08 708.44 688.95 707.06 705.22 1,096,636
Apr 29, 2026 705.11 708.80 668.85 686.36 684.57 1,834,985
Apr 28, 2026 751.37 754.00 730.90 731.77 729.87 569,174
Apr 27, 2026 745.47 756.40 743.61 744.44 742.50 603,283
Apr 24, 2026 760.00 761.96 736.71 751.57 749.62 809,546
Apr 23, 2026 750.99 767.21 747.26 766.02 764.03 928,723
Apr 22, 2026 751.48 755.78 740.47 746.58 744.64 901,955
Apr 21, 2026 746.20 751.54 734.12 747.36 745.42 707,466
Apr 20, 2026 750.00 755.59 744.00 749.41 747.46 493,842
Apr 17, 2026 754.74 758.61 746.91 750.57 748.62 512,998
Apr 16, 2026 749.56 756.00 742.68 746.00 744.06 505,374
Apr 15, 2026 758.67 760.58 739.12 753.93 751.97 571,311
Apr 14, 2026 744.97 757.68 743.71 755.51 753.54 637,779
Apr 13, 2026 747.74 756.90 737.34 746.46 744.52 747,093
Apr 10, 2026 771.48 771.48 739.09 748.87 746.92 751,457
Apr 9, 2026 764.15 772.45 761.50 767.85 765.85 596,831
Apr 8, 2026 765.26 775.62 755.99 775.53 773.51 580,427
Apr 7, 2026 758.40 761.91 747.76 760.27 758.29 620,874
Apr 6, 2026 766.83 768.80 758.49 763.04 761.05 460,419
Apr 2, 2026 767.04 770.11 745.00 761.85 759.87 1,000,702
Apr 1, 2026 775.00 781.21 769.97 777.25 775.23 627,412
Mar 31, 2026 757.47 774.26 755.80 772.64 770.63 642,702
Mar 30, 2026 743.83 757.68 741.47 749.29 747.34 630,455
Mar 27, 2026 756.65 759.47 736.64 737.71 735.79 492,197
Mar 26, 2026 749.40 761.73 747.77 756.73 754.76 488,587
Mar 25, 2026 744.67 757.98 744.02 749.47 747.52 553,090
Mar 24, 2026 728.51 743.16 727.96 741.69 739.76 507,979
Mar 23, 2026 745.00 750.00 735.00 736.53 734.61 535,936
Mar 20, 2026 738.17 744.85 728.64 732.87 730.96 1,359,993
Mar 19, 2026 744.50 750.32 727.88 737.45 735.53 628,268
Mar 18, 2026 751.22 757.60 734.56 744.12 742.18 672,598
Mar 17, 2026 763.53 771.23 755.63 759.05 757.08 437,038
Mar 16, 2026 750.00 763.30 747.01 756.91 754.94 396,216
Mar 13, 2026 754.55 758.98 741.89 745.77 743.83 438,297
Mar 12, 2026 764.06 766.00 744.00 746.61 744.67 630,421
Mar 11, 2026 769.17 783.12 765.00 774.66 772.64 405,249
Mar 10, 2026 781.67 788.69 771.34 772.03 770.02 473,422
Mar 9, 2026 759.86 783.70 754.91 781.60 779.57 697,070
Mar 6, 2026 755.01 762.40 746.66 759.86 757.88 561,908
Mar 5, 2026 780.00 781.99 760.01 764.93 762.94 657,525
Mar 4, 2026 767.05 791.60 764.24 787.50 785.45 641,608
Mar 3, 2026 781.01 794.77 764.49 766.66 764.66 637,256
Mar 2, 2026 771.10 793.16 769.63 790.81 788.75 793,325
Feb 27, 2026 760.91 786.68 760.91 781.67 779.64 726,380
Feb 26, 2026 784.28 784.50 753.79 770.79 768.78 772,714
Feb 25, 2026 774.13 791.11 771.43 784.28 782.24 751,069
Feb 24, 2026 780.47 792.67 768.75 772.19 770.18 628,679
Feb 23, 2026 777.58 792.15 777.58 787.04 784.99 510,650
Feb 20, 2026$0.94 dividend 775.00 781.46 770.00 779.67 777.64 615,295
Feb 19, 2026 790.00 790.00 773.31 782.38 779.40 505,091
Feb 18, 2026 793.53 797.00 786.79 792.16 789.15 675,897
Feb 17, 2026 803.48 815.00 783.62 793.53 790.51 747,143
Feb 13, 2026 788.92 806.18 785.00 803.17 800.12 974,845
Feb 12, 2026 784.80 796.72 774.72 783.65 780.67 814,483
Feb 11, 2026 750.85 781.42 745.07 778.97 776.01 1,123,719
Feb 10, 2026 779.73 781.40 753.10 754.91 752.04 792,677
Feb 9, 2026 783.17 790.00 775.50 780.28 777.31 586,816
Feb 6, 2026 769.63 786.99 764.78 785.51 782.52 671,659
Feb 5, 2026 777.83 790.00 760.00 766.63 763.72 976,458
Feb 4, 2026 765.80 779.78 765.21 775.06 772.11 952,077
Feb 3, 2026 745.53 773.72 742.74 759.18 756.29 768,694
Feb 2, 2026 732.92 763.56 731.51 755.02 752.15 693,090
Jan 30, 2026 753.96 774.37 735.61 741.45 738.63 1,317,891
Jan 29, 2026 755.73 755.73 742.80 749.44 746.59 925,773
Jan 28, 2026 765.15 766.99 747.57 751.13 748.27 827,944
Jan 27, 2026 762.47 776.25 761.50 771.25 768.32 645,805
Jan 26, 2026 750.09 767.30 750.09 762.65 759.75 934,312
Jan 23, 2026 757.31 762.00 747.30 753.55 750.68 721,175
Jan 22, 2026 750.34 765.00 747.37 755.51 752.64 765,689
Jan 21, 2026 736.71 750.00 735.00 749.33 746.48 788,543
Jan 20, 2026 729.40 737.87 718.38 733.78 730.99 789,339
Jan 16, 2026 749.09 749.09 726.43 733.04 730.25 1,682,566
Jan 15, 2026 754.85 756.50 737.00 741.92 739.10 865,627
Jan 14, 2026 760.58 766.64 753.01 754.14 751.27 669,119
Jan 13, 2026 765.16 765.99 743.94 758.91 756.02 946,732
Jan 12, 2026 810.00 811.09 765.08 768.00 765.08 1,321,289
Jan 9, 2026 802.97 821.11 790.88 796.55 793.52 711,556
Jan 8, 2026 805.81 816.99 800.68 801.01 797.96 1,049,326
Jan 7, 2026 786.18 814.10 780.10 812.27 809.18 1,264,733
Jan 6, 2026 764.35 787.66 763.20 776.54 773.59 935,119
Jan 5, 2026 769.72 771.99 753.20 763.23 760.33 835,909
Jan 2, 2026 774.25 779.75 765.77 776.31 773.36 464,826
Dec 31, 2025 772.00 775.00 769.17 771.87 768.93 355,156
Dec 30, 2025 776.30 777.77 770.30 773.94 771.00 383,233
Dec 29, 2025 780.56 785.05 774.60 780.50 777.53 545,104
Dec 26, 2025 783.79 788.01 778.04 784.97 781.99 321,114
Dec 24, 2025 787.99 792.77 783.61 783.71 780.73 267,162
Dec 23, 2025 777.36 792.75 777.00 785.17 782.18 832,013
Dec 22, 2025 765.84 783.60 765.09 779.36 776.40 818,007
Dec 19, 2025 753.72 773.85 748.18 767.96 765.04 2,336,025
Dec 18, 2025 747.54 752.84 739.23 748.71 745.86 1,057,594
Dec 17, 2025 746.55 751.99 743.33 749.79 746.94 766,045
Dec 16, 2025 752.57 757.35 734.72 746.36 743.52 713,243
Dec 15, 2025 748.85 756.67 746.38 752.62 749.76 932,936
Dec 12, 2025 741.59 746.05 734.38 741.29 738.47 804,841
Dec 11, 2025 726.08 753.61 726.08 746.80 743.96 1,153,882
Dec 10, 2025 695.06 728.00 692.50 726.21 723.45 1,316,662
Dec 9, 2025 705.11 711.15 691.86 692.58 689.95 604,535
Dec 8, 2025 723.69 724.13 701.75 703.26 700.59 1,005,953
Dec 5, 2025 723.00 736.15 717.26 718.36 715.63 798,452
Dec 4, 2025 732.45 735.00 721.22 722.80 720.05 1,067,133
Dec 3, 2025 730.36 744.23 720.07 723.67 720.92 1,238,676
Dec 2, 2025 742.12 747.00 731.00 742.00 739.18 924,677
Dec 1, 2025 775.60 779.92 748.15 750.11 747.26 992,389
Nov 28, 2025 784.70 788.98 779.50 780.19 777.22 510,377
Nov 26, 2025 785.72 790.98 777.00 784.61 781.63 871,691
Nov 25, 2025 764.88 790.57 760.00 787.32 784.33 1,200,573
Nov 24, 2025 759.05 773.13 756.64 761.45 758.55 1,554,940
Nov 21, 2025 736.01 764.09 735.74 755.90 753.02 1,427,897
Nov 20, 2025$0.88 dividend 725.00 753.51 720.02 737.00 734.20 2,297,145
Nov 19, 2025 727.81 727.81 702.63 702.75 699.24 1,383,591
Nov 18, 2025 702.51 727.97 699.22 725.34 721.72 1,368,882
Nov 17, 2025 693.34 711.88 692.29 704.31 700.79 1,133,105
Nov 14, 2025 697.19 699.27 685.95 693.50 690.04 907,089
Nov 13, 2025 683.00 713.58 679.93 694.99 691.52 1,505,339
Nov 12, 2025 678.89 690.78 672.67 681.72 678.32 1,208,307
Nov 11, 2025 651.48 676.33 651.38 674.55 671.18 977,533
Nov 10, 2025 656.00 665.99 653.19 654.74 651.47 824,903
Nov 7, 2025 650.35 658.21 640.99 657.53 654.25 782,810
Nov 6, 2025 640.83 657.00 640.83 646.87 643.64 916,868
Nov 5, 2025 631.10 646.89 628.00 644.19 640.98 724,423
Nov 4, 2025 643.78 646.22 625.14 628.00 624.87 1,031,189
Nov 3, 2025 657.46 657.46 627.50 642.25 639.04 810,538
Oct 31, 2025 649.45 660.00 645.00 651.80 648.55 798,001
Oct 30, 2025 645.56 664.00 643.91 654.04 650.78 1,120,676
Oct 29, 2025 650.41 659.98 637.66 652.91 649.65 1,751,496
Oct 28, 2025 612.02 655.70 605.03 654.48 651.21 2,126,839
Oct 27, 2025 580.50 586.14 575.93 585.31 582.39 1,246,122
Oct 24, 2025 579.65 582.70 576.20 577.95 575.07 875,474
Oct 23, 2025 579.68 584.00 572.75 575.69 572.82 779,106
Oct 22, 2025 580.21 588.71 578.60 584.74 581.82 691,262
Oct 21, 2025 574.60 582.40 572.82 579.34 576.45 651,765
Oct 20, 2025 579.41 582.64 574.23 576.77 573.89 639,173
Oct 17, 2025 570.35 579.04 566.11 578.05 575.16 745,708
Oct 16, 2025 583.01 589.08 564.00 569.17 566.33 842,249
Oct 15, 2025 575.03 584.87 569.02 576.42 573.54 927,747
Oct 14, 2025 556.92 576.18 553.87 572.60 569.74 1,010,700
Oct 13, 2025 551.50 563.77 541.00 557.73 554.95 1,426,513
Oct 10, 2025 569.29 577.17 555.54 564.63 561.81 1,495,028
Oct 9, 2025 569.02 574.72 563.51 569.90 567.06 853,522
Oct 8, 2025 584.01 605.00 560.97 563.86 561.05 1,415,840
Oct 7, 2025 587.59 591.45 578.42 583.24 580.33 656,378
Oct 6, 2025 602.00 603.65 584.41 585.48 582.56 1,072,437
Oct 3, 2025 602.09 618.01 599.87 600.00 597.00 1,154,866
Oct 2, 2025 600.42 605.41 596.60 600.00 597.00 1,096,615
Oct 1, 2025 570.87 615.39 569.99 599.94 596.95 2,083,171
Sep 30, 2025 560.58 574.04 555.00 562.27 559.46 1,662,880
Sep 29, 2025 563.90 564.91 557.34 560.75 557.95 922,537
Sep 26, 2025 562.00 564.61 550.71 563.90 561.09 838,628
Sep 25, 2025 577.30 579.00 549.20 555.51 552.74 1,394,243

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Regeneron Pharmaceuticals Inc Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at REGN, per a recent SEC DEF 14A filing. We estimate that the median employee at REGENERON PHARMACEUTICALS, INC. is paid $164,447.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation